Patents Examined by Laura M Daniel
  • Patent number: 10851075
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 1, 2020
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Patent number: 10851125
    Abstract: The present invention relates to novel forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate, pharmaceutical formulations, and therapeutic uses thereof in treating viral infections (e.g., an HIV infection).
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: December 1, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Olga Viktorovna Lapina, Bing Shi, Silas Wang
  • Patent number: 10836765
    Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: November 17, 2020
    Assignee: Aurobindo Pharma Ltd
    Inventors: Sandeep Jain, Komel Ansari, Subramanyam Maddala, Sivakumaran Meenakshisundaram
  • Patent number: 10836782
    Abstract: The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 17, 2020
    Assignees: The Medical College of Wisconsin, Inc., Aix-Marseille Universite
    Inventors: Balaraman Kalyanaraman, Jacek Michal Zielonka, Micael J. Hardy, Oliver Ouari, Ming You
  • Patent number: 10822338
    Abstract: The present invention is directed to compounds of generic formula (I): or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. The invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the A2A-receptor is involved. The invention further involves use of the compounds as an A2A-receptor antagonist and/or inhibitor for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the receptor, which includes central nervous system disorders such as Parkinson's disease. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: November 3, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Xianhai Huang, Yeon-Hee Lim, Rongze Kuang, Heping Wu, Rajan Anand, Younong Yu, Edward Metzger, Michael Man-Chu Lo, Pauline C. Ting, Andrew W. Stamford, Paul Tempest
  • Patent number: 10822325
    Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 3, 2020
    Inventors: Tudor I. Oprea, Cristian George Bologa, Oleg Ursu, Jun-Yong Choe, Cristina Iancu
  • Patent number: 10806723
    Abstract: The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 20, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mukesh Agarwal, David Wald, Mahesh Gundluru, Goutam Karan, Zhiqiang Xia
  • Patent number: 10800785
    Abstract: Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: October 13, 2020
    Assignees: Shanghai Fochon Pharmaceutical Co., Ltd., Fochon Pharmaceuticals, Ltd.
    Inventors: Xingdong Zhao, Weipeng Zhang, Zhifang Chen, Ling Chen, Xianlong Wang, Zhifu Li, Rui Tan, Lijun Yang, Haohan Tan, Bin Liu, Kai Ran, Zongyao Zou, Min Lin, Jing Sun, Weibo Wang
  • Patent number: 10784447
    Abstract: The present invention relates to: an organic compound represented by Chemical Formula 1; a composition for an organic optoelectronic diode containing the organic compound; and an organic optoelectronic diode to which the organic compound or the composition is applied. In Chemical Formula 1, Z, R1 to R11, and n1 to n4 are the same as those defined in the specification.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 22, 2020
    Assignee: SAMSUNG SDI CO., LTD.
    Inventors: Sujin Han, Dong Min Kang, Soohyun Min, Eun Sun Yu, Byoungkwan Lee, Hanill Lee, Sung-Hyun Jung, Ho Kuk Jung
  • Patent number: 10781214
    Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: September 22, 2020
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD.
    Inventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Hong Wu, Kailin Yu, Chen Hu, Wenchao Wang, Cheng Chen, Fengming Zou, Ziping Qi, Li Wang, Beilei Wang
  • Patent number: 10759781
    Abstract: The present invention provides a compound of general formula (I) (wherein, R1, X, p and q are as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 1, 2020
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Ken-ichi Komori, Akishi Ninomiya, Shigeru Ushiyama, Masaru Shinohara, Koji Ito, Tetsuo Kawaguchi, Yasunori Tokunaga, Hiroyoshi Kawada, Haruka Yamada, Yusuke Shiraishi, Masahiro Kojima, Masaaki Ito, Tomio Kimura
  • Patent number: 10752612
    Abstract: Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 25, 2020
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Timothy Gahman, Andrew Shiau
  • Patent number: 10752629
    Abstract: Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: August 25, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Stephen D. Meriney, Mary Liang
  • Patent number: 10745405
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Donna A. A. Wilton, Mandy M. Loo, Ryan Hudson, Patrick J. Brassil
  • Patent number: 10723716
    Abstract: The invention relates to compounds and pharmaceutical compositions capable of treating amyloid diseases and other diseases characterized by oligomerization and/or fibrillation of amyloidogenic peptides such as amyloid beta peptide (Abeta or A?).
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 28, 2020
    Assignee: NEW YORK UNIVERSITY
    Inventors: Sunil Kumar, Andrew D. Hamilton
  • Patent number: 10703725
    Abstract: An object of the present invention is to provide a novel tetrahydroazepine compound and a process for producing the same. The present invention relates to a tetrahydroazepine compound represented by the formula (10) or a salt thereof, and a process for producing the said compound or a salt thereof. (In the formula, R1 is an optionally substituted alkyl group, R2 is an optionally substituted alkyl group and one of the X—Y bond and the Y—Z bond is a carbon-carbon double bond and the other is a carbon-carbon single bond).
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 7, 2020
    Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Taizo Ito, Xiaoming Liao, Zihua Li
  • Patent number: 10689354
    Abstract: A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A-(CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 23, 2020
    Assignee: Teijin Pharma Limited
    Inventors: Shinnosuke Hosoda, Gen Unoki, Hidekazu Watanabe, Kosuke Sasaki, Jun Shibata, Emi Yokoyama, Kyohei Horie, Kenichiro Takagi
  • Patent number: 10683300
    Abstract: The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (“CHP”).
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: June 16, 2020
    Assignee: NovMetaPharma Co., Ltd.
    Inventors: Kay Olmstead, David Pearson, Elaine McPherson
  • Patent number: 10683292
    Abstract: There are provided substituted purine and 3-deazapurine analogues, which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, such as cancer, cell proliferative disorders, infectious diseases of different origin, immune-related disorders and neurodegenerative disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: June 16, 2020
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Elena Casale, Emiliana Corti, Paola Gnocchi, Marcella Nesi, Sten Christian Orrenius, Francesca Quartieri, Federico Riccardi Sirtori
  • Patent number: 10676452
    Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: June 9, 2020
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van Der Graaf, Robert Henk Henning, Leo Edwin Deelman, Gerrit Jan Willem Euverink